**Q&A COVID-19 Webinar**

**Question1:**

**So will we see consistently this U07.1 in the problem list tab in Medical Record?**

**This is a question you will need to ask your medical records department, to see how they will be using the code. As far as the use of U07.1 within this specific data item, follow the abstraction instructions.**

**Question 2:**

**Please say again when/what cases we begin collecting COVID-19 data items for. Thank you.**

**The following directions for recording COVID-19 information in the required data items are applicable to cases diagnosed January 1, 2020 or later and completed on or after June 1, 2020.**

**If you have cases that were abstracted before June 1st and have marked those cases as COVID patients and you would like to go back and abstract these data items you can, but it is not expected.**

**Question 3:**

**If there is "other TX like aspirin for heme disease" that is changed/delayed this is just captured under text field ? Also endocrine SX (like orchiectomy for prostate cancer or BSO for breast cancer) this is only captured in text field ? Just wanted to make sure... Thanks.**

**They are only asking about these data items. If there are any additional COVID related delays that you feel are important to the TX and care of the patient you can document those in the COVID—GENERAL TEXT Field.**

**Question 4:**

 **Pt has dx of DCIS, statement in chart that due to Covid-19 pt will be started on hormone therapy, but there is no statement regarding the surgical procedure. Because surgery would have been the treatment of choice due to guidelines, are we to assume that the surgery was delayed even though the physicians did not mention that surgery was the first choice?**

**Only record what you know. So it the original treatment plan did not mention surgery do not code the surgery field.**

**If there are any additional COVID related delays that you feel are important to the TX and care of the patient you can document those in the COVID—GENERAL TEXT Field.**

**Question 5:**

**Any idea how long we will be collecting these additional 16 data items related to COIVD-19 in our abstracts?**

**There has been no set end point. Given the impact that COVID-19 has had on cancer patients we will collect this data until we are told otherwise.**

**Question 6:**

**How often are we to look in the EMR for COVID19 testing?**

**If the case was fully abstracted before June 1st, you will not be required to go back and abstract these data items, unless it is required by your facility. If during follow up review, you see that a patient has tested positive, then abstract the test type and date, even if the test is administered after first course treatment.**

**Question 7:**

 **Is it only applicable during FCT?**

**The treatment data items are only in regards to first course treatment. As stated above you may update covid-19 testing results and date during follow-up.**

**Clarifications:**

**Clarification #1**

The instructions state that if treatment was recommended before but administered after disease progression, record surgical treatment in Second Course Rx fields. However, second course treatment should be recorded in second course treatment fields if those fields are being collected by the facility. If they are not collected, no need to record second course treatment.